World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
155
Citations
162458
World Ranking
926
National Ranking
527

Overview

F. Stephen Hodi is affiliated with Harvard University in the United States. Their primary field of study is Medicine, with a significant emphasis on Oncology. Within this domain, their research spans specialized subfields including Immunology, Molecular Biology, Pulmonary and Respiratory Medicine, and Cancer Research.

Their work extensively covers main research topics such as Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, and Immunotherapy and Immune Responses. Other notable topics include Melanoma and MAPK Pathways, Cancer Genomics and Diagnostics, Cutaneous Melanoma Detection and Management, and Colorectal Cancer Treatments and Studies.

F. Stephen Hodi has contributed numerous articles to a variety of scientific journals. Frequent publication venues include:

  • Journal of Clinical Oncology
  • Clinical Cancer Research
  • Annals of Oncology
  • Journal for ImmunoTherapy of Cancer
  • Cancer Research

Among recent papers authored or co-authored by Hodi are:

  • "A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors," 2020, Nature Medicine
  • "Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma," 2022, Zurich Open Repository and Archive (University of Zurich)
  • "Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy," 2020, Cell
  • "Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma," 2020, Cancer Cell
  • "Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors," 2021, Clinical Cancer Research

Frequent co-authors collaborating with Hodi include:

  • Michael P. Manos
  • Anita Giobbie-Hurder
  • Dirk Schadendorf
  • Scott J. Rodig
  • Georgina V. Long

Best Publications

  • Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.

    F. Stephen Hodi;Steven J. O'Day;David F. McDermott;Robert W. Weber

  • Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

    Suzanne L. Topalian;F. Stephen Hodi;Julie R. Brahmer;Scott N. Gettinger

  • Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

    James Larkin;Vanna Chiarion-Sileni;Rene Gonzalez;Jean Jacques Grob

  • Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

    Roy S. Herbst;Jean Charles Soria;Marcin Kowanetz;Gregg D. Fine

  • Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

    Jedd D. Wolchok;Vanna Chiarion-Sileni;Rene Gonzalez;Piotr Rutkowski

  • Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

    Omid Hamid;Caroline Robert;Adil Daud;F. Stephen Hodi

  • Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

    Jedd D. Wolchok;Axel Hoos;Steven O'Day;Jeffrey S. Weber

  • Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

    Michael A. Postow;Jason Chesney;Anna C. Pavlick;Caroline Robert

  • Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

    Jeffrey S Weber;Sandra P D'Angelo;David Minor;F Stephen Hodi

  • Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

    Suzanne L. Topalian;Mario Sznol;David F. McDermott;Harriet M. Kluger

  • Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.

    Nadeem Riaz;Jonathan J. Havel;Vladimir Makarov;Alexis Desrichard

  • iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

    Lesley Seymour;Jan Bogaerts;Andrea Perrone;Robert Ford

  • Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

    Dirk Schadendorf;F. Stephen Hodi;Caroline Robert;Jeffrey S. Weber

  • Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial

    Caroline Robert;Antoni Ribas;Jedd D. Wolchok;F. Stephen Hodi

  • Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade.

    Brian C. Miller;Debattama R. Sen;Debattama R. Sen;Rose Al Abosy;Rose Al Abosy;Kevin Bi;Kevin Bi

  • Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

    Antoni Ribas;Igor Puzanov;Reinhard Dummer;Dirk Schadendorf

  • Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

    Shohei Koyama;Esra A. Akbay;Yvonne Y. Li;Grit S. Herter-Sprie

  • RECIST 1.1—Update and clarification: From the RECIST committee

    Lawrence H. Schwartz;Lawrence H. Schwartz;Saskia Litiere;Elisabeth G. E. de Vries;Robert Ford

  • Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

    Antoni Ribas;Reinhard Dummer;Igor Puzanov;Ari VanderWalde

  • Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

    Alexander M M Eggermont;Vanna Chiarion-Sileni;Jean-Jacques Grob;Reinhard Dummer

Frequent Co-Authors

Jedd D. Wolchok
Jedd D. Wolchok Cornell University
David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center
Patrick A. Ott
Patrick A. Ott Harvard University
Scott J. Rodig
Scott J. Rodig Harvard University
Omid Hamid
Omid Hamid Cedars-Sinai Medical Center
Antoni Ribas
Antoni Ribas University of California, Los Angeles
Caroline Robert
Caroline Robert University of Paris-Saclay
Michael B. Atkins
Michael B. Atkins Georgetown University
Jeffrey S. Weber
Jeffrey S. Weber New York University
Jeffrey A. Sosman
Jeffrey A. Sosman Northwestern University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re exploring medical careers in the USA, online degrees offer flexible routes to enter and advance in the field. Many healthcare professionals are seeking the shortest dnp programs to accelerate their journeys to leadership roles or advanced clinical practice.

For those aiming to complete their Doctor of Nursing Practice in record time, options like a 1 year dnp program online can be particularly appealing. These intensive programs are designed for motivated nurses who want to earn credentials quickly and efficiently.

Entry-level programs are also in high demand. Prospective nurses often look for online lpn programs to enter the workforce with practical skills in a shorter timeframe.

Specialization is another key consideration. Those interested in mental health might pursue the shortest pmhnp program to become a Psychiatric Mental Health Nurse Practitioner quickly.

Whether starting or advancing your medical career, these online pathways provide options to fit different goals, backgrounds, and timelines.

Best Scientists Citing F. Stephen Hodi

Trending Scientists